Low-density lipoprotein receptor overexpression enhances the rate of brain-to-blood Aβ clearance in a mouse model of β-amyloidosis

Proceedings of the National Academy of Sciences of the United States of America

Volumn 109, Issue 38, 2012, Pages 15502-15507

  Castellano, Joseph M ^a   Deane, Rashid ^b   Gottesdiener, Andrew J ^a   Verghese, Philip B ^a   Stewart, Floy R ^a   West, Tim ^c   Paoletti, Andrew C ^c   Kasper, Tristan R ^b   DeMattos, Ronald B ^d   Zlokovic, Berislav V ^e   Holtzman, David M ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

^c Center for Emerging Technologies   (United States)

^d ELI LILLY AND COMPANY   (United States)

^e UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

Dementia; In vivo microdialysis; Low density lipoprotein related protein 1; Peripheral; Sequestration

Indexed keywords

AMYLOID BETA PROTEIN; AMYLOID BETA PROTEIN ANTIBODY; LOW DENSITY LIPOPROTEIN RECEPTOR;

AMYLOIDOSIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BETA AMYLOIDOSIS; BLOOD BRAIN BARRIER; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN DEGRADATION; PROTEIN EXPRESSION;

ALLELES; AMYLOID BETA-PEPTIDES; AMYLOIDOSIS; ANIMALS; APOLIPOPROTEIN E4; BLOOD-BRAIN BARRIER; BRAIN; DISEASE MODELS, ANIMAL; INSULIN; KINETICS; MICE; MICE, INBRED C57BL; MICE, INBRED DBA; MICE, TRANSGENIC; MICRODIALYSIS; RECEPTORS, LDL; TRANSGENES;

MUS;

EID: 84866539065     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1206446109     Document Type: Article

References (51)

1. Hardy J (2006) A hundred years of Alzheimer's disease research. Neuron 52:3-13.
2. Golde TE, Schneider LS, Koo EH (2011) Anti-aβ therapeutics in Alzheimer's disease: The need for a paradigm shift. Neuron 69:203-213.
3. Benilova I, Karran E, De Strooper B (2012) The toxic Aβ oligomer and Alzheimer's disease: An emperor in need of clothes. Nat Neurosci 15:349-357.
4. Mawuenyega KG, et al. (2010) Decreased clearance of CNS beta-amyloid in Alzheimer's disease. Science 330:1774.
5. Verghese PB, Castellano JM, Holtzman DM (2011) Apolipoprotein E in Alzheimer's disease and other neurological disorders. Lancet Neurol 10:241-252.
6. Reiman EM, et al. (2009) Fibrillar amyloid-beta burden in cognitively normal people at 3 levels of genetic risk for Alzheimer's disease. Proc Natl Acad Sci USA 106:6820-6825.
7. Morris JC, et al. (2010) APOE predicts amyloid-beta but not tau Alzheimer pathology in cognitively normal aging. Ann Neurol 67:122-131.
8. Schmechel DE, et al. (1993) Increased amyloid beta-peptide deposition in cerebral cortex as a consequence of apolipoprotein E genotype in late-onset Alzheimer disease. Proc Natl Acad Sci USA 90:9649-9653. (Pubitemid 23315843)
9. Tiraboschi P, et al. (2004) Impact of APOE genotype on neuropathologic and neurochemical markers of Alzheimer disease. Neurology 62:1977-1983. (Pubitemid 38738207)
10. Sunderland T, et al. (2004) Cerebrospinal fluid beta-amyloid1-42 and tau in control subjects at risk for Alzheimer's disease: The effect of APOE epsilon4 allele. Biol Psychiatry 56:670-676. (Pubitemid 39446849)
11. Castellano JM, et al. (2011) Human apoE isoforms differentially regulate brain amyloid-β peptide clearance. Sci Transl Med 3:89ra57.
12. Bales KR, et al. (2009) Human APOE isoform-dependent effects on brain beta-amyloid levels in PDAPP transgenic mice. J Neurosci 29:6771-6779.
13. Bell RD, et al. (2007) Transport pathways for clearance of human Alzheimer's amyloid beta-peptide and apolipoproteins E and J in the mouse central nervous system. J Cereb Blood Flow Metab 27:909-918. (Pubitemid 46659038)
14. Deane R, et al. (2004) LRP/amyloid beta-peptide interaction mediates differential brain efflux of Abeta isoforms. Neuron 43:333-344. (Pubitemid 39061126)
15. Deane R, et al. (2008) apoE isoform-specific disruption of amyloid beta peptide clearance from mouse brain. J Clin Invest 118:4002-4013.
16. Fryer JD, et al. (2005) The low density lipoprotein receptor regulates the level of central nervous system human and murine apolipoprotein E but does not modify amyloid plaque pathology in PDAPP mice. J Biol Chem 280:25754-25759. (Pubitemid 40962285)
17. Cao D, Fukuchi K, Wan H, Kim H, Li L (2006) Lack of LDL receptor aggravates learning deficits and amyloid deposits in Alzheimer transgenic mice. Neurobiol Aging 27:1632-1643. (Pubitemid 44344838)
18. Kim J, et al. (2009) Overexpression of low-density lipoprotein receptor in the brain markedly inhibits amyloid deposition and increases extracellular A beta clearance. Neuron 64:632-644.
19. Katsouri L, Georgopoulos S (2011) Lack of LDL receptor enhances amyloid deposition and decreases glial response in an Alzheimer's disease mouse model. PLoS ONE 6:e21880.
20. Shibata M, et al. (2000) Clearance of Alzheimer's amyloid-ss(1-40) peptide from brain by LDL receptor-related protein-1 at the blood-brain barrier. J Clin Invest 106:1489-1499. (Pubitemid 32038587)
21. Fullerton SM, Shirman GA, Strittmatter WJ, Matthew WD (2001) Impairment of the blood-nerve and blood-brain barriers in apolipoprotein e knockout mice. Exp Neurol 169:13-22. (Pubitemid 32427699)
22. Methia N, et al. (2001) ApoE deficiency compromises the blood brain barrier especially after injury. Mol Med 7:810-815. (Pubitemid 34175304)
23. Macauley SL, Pekny M, Sands MS (2011) The role of attenuated astrocyte activation in infantile neuronal ceroid lipofuscinosis. J Neurosci 31(43):15575-15585.
24. Abbott NJ, Rönnbäck L, Hansson E (2006) Astrocyte-endothelial interactions at the blood-brain barrier. Nat Rev Neurosci 7:41-53. (Pubitemid 41828930)
25. Armulik A, et al. (2010) Pericytes regulate the blood-brain barrier. Nature 468(7323):557-561.
26. Yamada K, et al. (2008) The low density lipoprotein receptor-related protein 1 mediates uptake of amyloid beta peptides in an in vitro model of the blood-brain barrier cells. J Biol Chem 283:34554-34562.
27. Ghiso J, et al. (2004) Systemic catabolism of Alzheimer' s Abeta40 and Abeta42. J Biol Chem 279:45897-45908. (Pubitemid 39491582)
28. Barten DM, et al. (2005) Dynamics of beta-amyloid reductions in brain, cerebrospinal fluid, and plasma of beta-amyloid precursor protein transgenic mice treated with a gamma-secretase inhibitor. J Pharmacol Exp Ther 312:635-643. (Pubitemid 40189561)
29. Johnson-Wood K, et al. (1997) Amyloid precursor protein processing and A beta42 deposition in a transgenic mouse model of Alzheimer disease. Proc Natl Acad Sci USA 94:1550-1555.
30. DeMattos RB, et al. (2001) Peripheral anti-A beta antibody alters CNS and plasma A beta clearance and decreases brain A beta burden in a mouse model of Alzheimer's disease. Proc Natl Acad Sci USA 98:8850-8855. (Pubitemid 32678116)
31. Seubert P, et al. (2008) Antibody capture of soluble Abeta does not reduce cortical Abeta amyloidosis in the PDAPP mouse. Neurodegener Dis 5:65-71.
32. DeMattos RB, Bales KR, Cummins DJ, Paul SM, Holtzman DM (2002) Brain to plasma amyloid-beta efflux: A measure of brain amyloid burden in a mouse model of Alzheimer's disease. Science 295:2264-2267. (Pubitemid 34258840)
33. Hardy J, Selkoe DJ (2002) The amyloid hypothesis of Alzheimer's disease: Progress and problems on the road to therapeutics. Science 297:353-356. (Pubitemid 34790756)
34. Bu G (2009) Apolipoprotein E and its receptors in Alzheimer's disease: pathways, pathogenesis and therapy. Nat Rev Neurosci 10:333-344.
35. Brown MS, Goldstein JL (1986) A receptor-mediated pathway for cholesterol homeostasis. Science 232:34-47. (Pubitemid 16037973)
36. Cam JA, Zerbinatti CV, Li Y, Bu G (2005) Rapid endocytosis of the low density lipoprotein receptor-related protein modulates cell surface distribution and processing of the beta-amyloid precursor protein. J Biol Chem 280:15464-15470. (Pubitemid 40562905)
37. Andersen OM, et al. (2005) Neuronal sorting protein-related receptor sorLA/LR11 regulates processing of the amyloid precursor protein. Proc Natl Acad Sci USA 102:13461-13466. (Pubitemid 41420870)
38. Cam JA, et al. (2004) The low density lipoprotein receptor-related protein 1B retains beta-amyloid precursor protein at the cell surface and reduces amyloid-beta peptide production. J Biol Chem 279:29639-29646. (Pubitemid 38915847)
39. Fuentealba RA, et al. (2007) ApoER2 expression increases Abeta production while decreasing Amyloid Precursor Protein (APP) endocytosis: Possible role in the partitioning of APP into lipid rafts and in the regulation of gamma-secretase activity. Mol Neurodegener 2:14.
40. Kinoshita A, et al. (2001) Demonstration by fluorescence resonance energy transfer of two sites of interaction between the low-density lipoprotein receptor-related protein and the amyloid precursor protein: Role of the intracellular adapter protein Fe65. J Neurosci 21:8354-8361. (Pubitemid 33051433)
41. Trommsdorff M, Borg JP, Margolis B, Herz J (1998) Interaction of cytosolic adaptor proteins with neuronal apolipoprotein E receptors and the amyloid precursor protein. J Biol Chem 273:33556-33560. (Pubitemid 29005740)
42. Ulery PG, et al. (2000) Modulation of beta-amyloid precursor protein processing by the low density lipoprotein receptor-related protein (LRP). Evidence that LRP contributes to the pathogenesis of Alzheimer ' s disease. J Biol Chem 275:7410-7415. (Pubitemid 30146296)
43. DeMattos RB, et al. (2004) ApoE and clusterin cooperatively suppress Abeta levels and deposition: evidence that ApoE regulates extracellular Abeta metabolism in vivo. Neuron 41:193-202. (Pubitemid 38125181)
44. Basak JM, Verghese PB, Yoon H, Kim J, Holtzman DM (2012) Low-density lipoprotein receptor represents an apolipoprotein E-independent pathway of Aβ uptake and degradation by astrocytes. J Biol Chem 287:13959-13971.
45. Yamamoto T, Choi HW, Ryan RO (2008) Apolipoprotein E isoform-specific binding to the low-density lipoprotein receptor. Anal Biochem 372:222-226. (Pubitemid 350116770)
46. Knouff C, et al. (2004) Defective VLDL metabolism and severe atherosclerosis in mice expressing human apolipoprotein E isoforms but lacking the LDL receptor. Biochim Biophys Acta 1684:8-17. (Pubitemid 39140864)
47. Bien-Ly N, Gillespie AK, Walker D, Yoon SY, Huang Y (2012) Reducing human apolipoprotein E levels attenuates age-dependent Aβ accumulation in mutant human amyloid precursor protein transgenic mice. J Neurosci 32:4803-4811.
48. Kim J, et al. (2011) Haploinsufficiency of human APOE reduces amyloid deposition in a mouse model of amyloid-beta amyloidosis. J Neurosci 31(49):18007-18012.
49. Yamada K, et al. (2009) Abeta immunotherapy: Intracerebral sequestration of Abeta by an anti-Abeta monoclonal antibody 266 with high affinity to soluble Abeta. J Neurosci 29:11393-11398.
50. Sadowski MJ, et al. (2006) Blocking the apolipoprotein E/amyloid-beta interaction as a potential therapeutic approach for Alzheimer's disease. Proc Natl Acad Sci USA 103: 18787-18792. (Pubitemid 44913488)
51. Cramer PE, et al. (2012) ApoE-directed therapeutics rapidly clear β-amyloid and reverse deficits in AD mouse models. Science 335:1503-1506.